AI has potential to guide glaucoma management
Click Here to Manage Email Alerts
ORLANDO, Fla. – Artificial intelligence can reliably detect the glaucomatous disc; however, it is not yet FDA approved for use in clinical management due to the lack of biomarkers, Louis R. Pasquale, MD, FARVO, said here at the Optometric Glaucoma Society meeting, held prior to the American Academy of Optometry meeting.
AI must accurately diagnose disease onset and progression, establish appropriate target IOP and how it should be achieved, and predict clinical course, he said.
“However, FDA approvals for AI don’t include glaucoma because they feel we don’t have enough biomarkers for this to work.”
AI must detect functional damage in visual field testing, he said.
“There is great promise for AI in terms of helping us identify potential progression,” Pasquale said. “We have visual field reading centers, and they’re expensive. If you had an algorithm that could do this, you wouldn’t need a reading center.”
He said AI will have a big impact on disease detection.
“You screen people and tell them they have glaucoma, and they may not believe it,” he said. “People believe their phones.”
Pasquale envisions the “tele-glaucoma strategy of the future,” where patients have a glaucoma genetic risk score calculator on their phones, they can take a “selfie,” and the AI will indicate glaucoma or no glaucoma.
“When you find this information out in a very personal way, I think you’ll be more actionable about it,” he said. – by Nancy Hemphill, ELS, FAAO
Reference:
Pasquale LR. Can AI help you with managing glaucoma? Presented at: Optometric Glaucoma Society meeting; Orlando, Fla.; October 22, 2019.
Disclosure: Pasquale reports he is an advisor to Verily.
Collapse
Read more about
Click Here to Manage Email Alerts